CN104983758B - A kind of medicinal usage of Fructus Terminaliae Billericae extract - Google Patents
A kind of medicinal usage of Fructus Terminaliae Billericae extract Download PDFInfo
- Publication number
- CN104983758B CN104983758B CN201510341609.XA CN201510341609A CN104983758B CN 104983758 B CN104983758 B CN 104983758B CN 201510341609 A CN201510341609 A CN 201510341609A CN 104983758 B CN104983758 B CN 104983758B
- Authority
- CN
- China
- Prior art keywords
- fructus
- terminaliae billericae
- extract
- water
- ethyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a kind of medicinal usages of Fructus Terminaliae Billericae extract, and in particular to the application of Fructus Terminaliae Billericae extract and terminaliae billericae,fructus polyphenol in preparation treatment antihyperuricemic disease drug.Above-mentioned Fructus Terminaliae Billericae extract and terminaliae billericae,fructus polyphenol have the activity for inhibiting xanthine oxidase, the uric acid concentration in hyperuricemia model mouse blood can be effectively reduced, have the function for the treatment of hyperuricemia, while to metabolic disorder relevant to hyperuricemia: gout can play preferable curative effect.
Description
Technical field
The present invention relates to a kind of medicinal usages of Fructus Terminaliae Billericae extract, belong to field of traditional Chinese medicine preparation.
Background technique
In recent years, as the improvement of people's living standards, dietary structure changes, the intake of sugar, fat, protein
It obviously increases, the disease incidence of hyperuricemia and gout increasingly increases, oneself becomes a kind of common disease.
It is generally acknowledged that being hyperuricemia when 416 μm of ol/L of blood uric acid, about 5%-l2% Patients with Hyperuricemia can develop
As gout.Clinical characters are: gouty acute arthritis recurrent exerbation, tophaceous deposition, characteristic chornic arthritis and pass
Section deformity, often involves kidney and arteriosclerotic kidney and kidney calculus urate is caused to be formed.The acute attack of gout is Monosodium urate
Acute inflammation caused by (monosodium urate crystal, MSU) is deposited in crystalline form in joint and periarticular tissue
Disease reaction.Gout can not only invade bone and joint, but also be also easy to involve kidney and cardiovascular system.Hyperuricemia and original
The hair property diseases such as gout and obesity, hyperlipidemia, high blood pressure, diabetes, atherosclerosis are positively correlated in significant.Cause
This, hyperuricemia is to endanger a kind of serious metabolic disease of human health.
Currently, to the control of uric acid in blood being realized by two kinds of approach: first is that inhibiting the generation of uric acid.Uric acid be by
The effect of hypoxanthine and xanthine through xanthine oxidase and generate, it is yellow fast that xanthine oxidase is that hypoxanthine is converted into
Purine and xanthine are converted into enzyme necessary to uric acid, and an effective way for treating gout is to inhibit xanthine oxidase
(xanthine oxidase, XO) activity, to inhibit the formation of uric acid.The drug such as allopurinol for inhibiting uric acid to generate, it is non-
Cloth sotan.Second is that promoting the excretion of uric acid, promote drug such as probenecid, Benzbromarone of uric acid excretion etc..But said medicine poison
Side effect is big, such as allopurinol can cause allergy (incidence 10-15%), super quick syndrome (27.5% maculopapule trouble
Person is dead), the serious toxic side effect such as bone marrow suppression；Probenecid, Benzbromarone have gastrointestinal reaction, renal colic and excitation gout
The side effects such as acute attack limit the clinical application of these drugs to a certain extent.Therefore, novel high-efficiency low-toxicity is found
Antigout and antihyperuricemic disease drug be still a hot spot of current study of pharmacy.
Terminaliae billericae,fructus adjoins the drying of Li Le (Terminalia bellirica (Gaertn.) Roxb.) for combretaceae plant
Ripening fruits is Tibetan conventional crude drugs, and with myrobalan, emblic, Tibetan is referred to as " three fruits ", is the base of most of common prescriptions
Plinth.Terminaliae billericae,fructus is derived from India, is most commonly used medicinal plant in Ayurvedic medicine, pericarp for treat fever,
Cough, diarrhea, dysentery and skin disease, are passed to China with Buddhist sutra thereafter.It is received in 2010 editions Pharmacopoeias of the People's Republic of China
In Tibetan's proved recipe of load, there are five types of contain terminaliae billericae,fructus in proved recipe.Terminaliae billericae,fructus bitter, puckery, mild-natured, clearing heat and detoxicating, convergence blood-nourishing, tune
With all medicines, it to be used for various heat symptom-complexs, dysentery, grasserie, liver and bladder disease, eak after being ill.In modern medicine to the experimental study of terminaliae billericae,fructus
In, (Tibetan medicine terminaliae billericae,fructus, myrobalan and terminaliae billericae,fructus are in the Yunnan influence [J] of experimental animal internal organs cAMP, cGMP content by Zhang Jizhong
Cure J Chinese, 2009,30 (6): 53-55.) radioimmunology is used, terminaliae billericae,fructus is measured to mouse internal organs cAMP, cGMP content
Impression, as a result, it has been found that, there were significant differences to cAMP/cGMP value in stomach and bladder for terminaliae billericae,fructus, show may its by adjusting
CAMP/cGMP ratio and play the role of disease preventing and treating.Anwarul Hassan Gilani(Gilani A H,Khan A,Ali
T, et al.Mechanisms underlying the antispasmodic and bronchodilatory
Properties of Terminalia bellerica fruit [J] .Journal of ethnopharmacology,
2008,116 (3): 528-538.) experiment in vitro and experiment in vivo of terminaliae billericae,fructus crude extract are expanded, terminaliae billericae,fructus is studied in intestines
Pharmacological principle in terms of stomach is hyperfunction and respiratory disease, the results show that terminaliae billericae,fructus has anticholinergic and Ca2+Antagonist
Double action, to explain its folk custom usage in terms of colic pain, diarrhea and asthma.
Chinese patent literature CN 1410107A discloses a kind of xiatare tablet oral medicine, which is by Herba Euphorbiae Humifusae, myrobalan
Meat, Fructus Terminaliae Billericae, scarmonia ester, aloe, FRUCTUS TERMINALIAE IMMATURUS medicinal material composition, in clinical application many years, to skins such as treatment psoriasis
Skin disease curative effect is good.Chinese patent literature CN102441081A discloses a kind of drug for treating goat, is a kind of Tibetan medicine,
Also known as 14 taste gout, wherein active group be grouped into Herba Lycopodii, myrobalan, Rhizoma Acori Calami, cassia seed, match northern corydalis, terminaliae billericae,fructus,
Olibanum, Semen seu folium abelmoschi moschati, styrax, catechu, ichor cream, emblic, radix aucklandiae, red metal ash are prepared according to a certain weight ratio, have
Wind-dispelling, dehumidifying, anti-inflammatory analgetic, the function of dry yellow water are used for arthritis, rheumatoid arthritis, gout, four limbs caused by numbness is sick
Arthrocele pain, deformation, four limbs are stiff, yellow water accumulation etc..Include terminaliae billericae,fructus composition apply at home it is more, still
The ingredient and work not contained to terminaliae billericae,fructus itself are used as further research.
Summary of the invention
For this purpose, terminaliae billericae,fructus itself in the prior art contains ingredient and effect is unclear in order to solve, a kind of hair is provided and is scolded
The medicinal usage of seed extract.
The present invention provides application of the Fructus Terminaliae Billericae extract in preparation treatment antihyperuricemic disease drug.
It is the present invention also provides Fructus Terminaliae Billericae extracts caused by preparation treatment is due to hyperuricemia acute gout, slow
Property gout, gouty arthritis, gout breaking-out, the application in uric acid nephrolithiasis and gouty nephropathy drug.
In above-mentioned application, the Fructus Terminaliae Billericae extract is prepared by following methods: terminaliae billericae,fructus is impregnated at 20-80 DEG C
In solvent, filtering obtains terminaliae billericae,fructus extracting solution, is concentrated, and obtains Fructus Terminaliae Billericae extract, and the solvent is water, in methanol, ethyl alcohol
One or more mixed liquors.
In above-mentioned application, the preparation method of Fructus Terminaliae Billericae extract further includes that Fructus Terminaliae Billericae extract is further refined to purification,
The purification purification is macroporous adsorption resin chromatography.
In the above method, the macroporous adsorption resin chromatography the following steps are included: macroporous absorbent resin is taken to be chromatographed, according to
The secondary ethanol solution with water, 25v%-50v% elutes, then is eluted with the ethanol solution of 65v%-95v%, will after elution
Water elution is concentrated to dryness to arrive the Fructus Terminaliae Billericae extract of purification.
Terminaliae billericae,fructus Determination of Polyphenols is 10%-80% in the Fructus Terminaliae Billericae extract.
The present invention also provides application of the terminaliae billericae,fructus total polyphenols in preparation treatment antihyperuricemic disease drug.
It is present invention provides terminaliae billericae,fructus total polyphenols caused by preparation treatment is due to hyperuricemia acute gout, slow
Property gout, gouty arthritis, gout breaking-out, the application in uric acid nephrolithiasis and gouty nephropathy drug.
The present invention also provides a kind of for treating the drug of hyperuricemia, and the drug is to live with terminaliae billericae,fructus total polyphenols
Property ingredient, customary adjuvant be added in the Fructus Terminaliae Billericae extract of Xiang Hanyou terminaliae billericae,fructus total polyphenols be made according to common process and clinically may be used
Capsule, tablet, pill, granule, paste, mixture, the suspension of receiving.
The present invention also provides purposes of the said medicine in the drug of preparation treatment hyperuricemia.
Compared with prior art, the invention has the following advantages that
The Fructus Terminaliae Billericae extract and terminaliae billericae,fructus total polyphenols of preparation of the invention have the activity for inhibiting xanthine oxidase,
Preferable therapeutic effect is embodied in hyperuricemia model zoopery, facilitates hyperuricemia and hyperuricemia simultaneously
Send out the treatment and prevention of disease.
Specific embodiment
It below will the present invention will be described in further detail by specific example.It should be appreciated that tool described herein
Body embodiment only to explain the present invention, is not intended to limit the present invention.
Terminaliae billericae,fructus is purchased from Bozhou medicinal material market
The preparation of 1 Fructus Terminaliae Billericae extract of embodiment
2kg terminaliae billericae,fructus is taken, after crushing, after 70v% ethyl alcohol soaking at room temperature 7 days of 16L, extracting solution is filtered out, into filter residue
The 70v% ethyl alcohol of 12L is added, is impregnated 5 days, filtering merges extracting solution twice, obtains terminaliae billericae,fructus extracting solution, be concentrated in vacuo to
It is dry, obtain 679g terminaliae billericae,fructus crude extract (number TB-1), yield 33.9%.
The preparation of 2 Fructus Terminaliae Billericae extract of embodiment
2000g terminaliae billericae,fructus is taken, after crushing, 50min is extracted at 80 DEG C with the water of 16L, filters out extracting solution, again into filter residue
The water of 12L is added, 30min is extracted at 80 DEG C, filters, merges extracting solution twice, obtains terminaliae billericae,fructus extracting solution, be concentrated in vacuo to
It is dry, obtain 830g terminaliae billericae,fructus crude extract (number TB-2), yield 41.5%.
The preparation of 3 Fructus Terminaliae Billericae extract of embodiment
2000g terminaliae billericae,fructus is taken, 60min is extracted at 60 DEG C with the 80v% methanol of 16L after crushing, filters out extracting solution, to filter
The water that 12L is added in slag extracts 40min at 60 DEG C, and filtering merges extracting solution twice, obtains terminaliae billericae,fructus extracting solution, vacuum
It is concentrated to dryness, obtains 597g terminaliae billericae,fructus crude extract (number TB-3), yield 29.8%.
The purification of 4 Fructus Terminaliae Billericae extract of embodiment purifies
Terminaliae billericae,fructus crude extract (number TB-1) 200g is purification raw material in Example 1, with D101 type macroporous absorption
Resin is chromatographed.The quality of extract and the mass ratio of resin are 1:20.Successively use water, 50v% ethyl alcohol, 95v% ethyl alcohol into
Row gradient elution, the column volume of 5 times of each gradient elution, flow velocity are 2 times of column volume/hours.After elution, by water elution
Liquid, 50v% ethanol eluate, 95v% ethanol eluate are concentrated to dryness to arrive the Fructus Terminaliae Billericae extract of purification.
Terminaliae billericae,fructus crude extract (number TB-2) 200g is purification raw material in Example 2, big with Diaion-HP20 type
Macroporous adsorbent resin is chromatographed.The quality of extract and the mass ratio of resin are 1:20.Successively use water, 25v% ethyl alcohol, 65v%
Ethyl alcohol carries out gradient elution, the column volume of 5 times of each gradient elution, and flow velocity is 2 times of column volume/hours.After elution, by water
Eluent, 25v% ethanol eluate, 65v% ethanol eluate are concentrated to dryness to arrive the Fructus Terminaliae Billericae extract of purification.
In embodiment of the present invention, D101 type macroporous absorbent resin knows the limited public affairs of scientific and technological new material share purchased from Xi'an indigo plant
Department, Diaion-HP20 type macroporous absorbent resin are purchased from Mitsubishi Chemical Co., Ltd..D101 macroporous absorbent resin and Diaion
HP-20 is a kind of polystyrene type resin, the resin, such as AB-8, HPD-200, XAD-1600 etc. of the other producers of same-type
Resin also has similar effect, and indifference.Each purification extract yield and number are as shown in table 1.
1 terminaliae billericae,fructus of table purification purification experimental result
Capsule of the embodiment 5 containing Fructus Terminaliae Billericae extract
The capsule of the present embodiment includes following component:
Preparation method includes the following steps:
The Fructus Terminaliae Billericae extract and each pharmaceutic adjuvant of above-mentioned recipe quantity are weighed, is uniformly mixed, crosses 60 meshes three times, is packed into glue
Capsule to obtain the final product.
Tablet of the embodiment 6 containing Fructus Terminaliae Billericae extract
The tablet of the present embodiment includes following component:
Preparation method includes the following steps:
Purification Fructus Terminaliae Billericae extract, starch and the L-HPC for weighing above-mentioned recipe quantity are uniformly mixed, and cross 60 meshes three times, then
Suitable 10% starch slurry softwood is added thereto, then pelletizes, it is dry, after whole grain, superfine silica gel powder, magnesium stearate, cream is added
Sugar is uniformly mixed, and tabletting, film coating to obtain the final product.
Pill of the embodiment 7 containing Fructus Terminaliae Billericae extract
The pill of the present embodiment includes following component:
The Fructus Terminaliae Billericae extract for being TB-3, Glucose Liquid, ethyl alcohol are numbered in embodiment 3.
Preparation method includes the following steps:
Weigh above-mentioned Fructus Terminaliae Billericae extract, with suitable quantity of water, Glucose Liquid and ethyl alcohol as excipients, using generic method system
Make the water-bindered pill to get.
It should be noted that customary adjuvant used in embodiment 5-7 includes but is not limited to filler, disintegrating agent, lubrication
The mixture of one or more of agent, adhesive, corrigent, suspending agent, preservative.
Specifically, the filler also can be replaced pregelatinized starch, mannitol, chitin, microcrystalline cellulose, sucrose
One of or a variety of mixtures；
The disintegrating agent also can be replaced starch, crospovidone, sodium carboxymethylcellulose, one in sodium carboxymethyl starch
Kind or a variety of mixtures；
The lubricant also can be replaced one of talcum powder, silica, lauryl sodium sulfate or a variety of mixed
Close object；
The suspending agent also can be replaced one of polyvinylpyrrolidone, sucrose, agar, hydroxypropyl methyl cellulose
Or a variety of mixture；
The preservative also can be replaced one of parabens, benzoic acid, sodium benzoate, sorbic acid, sorbate
Or a variety of mixture；
Described adhesive also can be replaced one of polyvinylpyrrolidone, hydroxypropyl methyl cellulose or a variety of mixed
Close object；
The corrigent also can be replaced sweetener and/or essence；The sweetener be saccharin sodium, aspartame, sucrose,
One of honey element or a variety of mixtures；
Certainly, the customary adjuvant includes but is not limited to the above-mentioned range enumerated, and those skilled in the art can be according to reality
Situation does the selection and adjustment of adaptability.
Embodiment 8
Following experiment has been carried out in order to verify the technical effects of the present invention:
The measurement of the total polyphenols of Fructus Terminaliae Billericae extract
In this experimental example, Fructus Terminaliae Billericae extract (TB-1, TB-2, TB-3, TB-1W, TB-15, TB-19, TB-2W, TB-23,
TB-27 the measurement of the total polyphenols in) refers to the detection method of national standard GBT 8313-2008 Tea Polyphenols in Tea content, uses forint
Phenol reagent detects polyphenol content.
Specifically includes the following steps:
1, the preparation of forint phenol (Folin-Ciocalteu) reagent of 10v%: by 20ml forint phenol (Folin-
Ciocalteu) agent transfer with water constant volume and shakes up into 200ml volumetric flask.
2, the Na of 7.5w%2CO3The preparation of solution: the Na of 37.50g is weighed2CO3, add suitable quantity of water to dissolve, be transferred to 500ml
In volumetric flask, with water constant volume and shake up.
3, the preparation of gallic acid Standard Stock solutions (1000 μ g/ml): the gallic acid of 0.100g is weighed, in 100ml
Scale is dissolved and be settled in volumetric flask, is shaken up.
4, the preparation of gallic acid working solution: 1.0ml, 2.0ml, 3.0ml, 4.0ml, 5.0ml are pipetted respectively with pipette
Gallic acid standard reserving solution, be placed in 100ml volumetric flask, be settled to scale with water respectively, shake up and be respectively to get concentration
The gallic acid working solution of 10 μ g/ml, 20 μ g/ml, 30 μ g/ml, 40 μ g/ml, 50 μ g/ml.
5, the production of gallic acid standard curve: gallic acid working solution 1.0ml is pipetted respectively with pipette in graded tube
It is interior, it is separately added into 5.0ml forint phenol (Folin-Ciocalteu) in each test tube, shakes up.In reaction 3-8 minutes, it is added
The Na of 4.0ml2CO3Solution adds water to be settled to scale, shakes up.It places 60 minutes at room temperature, with the cuvette of 10mm, in 765nm
Spectrophotometric determination absorbance is used under wavelength condition, according to gallic acid working solution concentration and corresponding absorbance, production mark
Directrix curve.
6, Fructus Terminaliae Billericae extract (TB-1, TB-2, TB-3, TB-1W, TB-15, TB-19, TB-2W, TB-23, TB-27) is taken
It is made into the sample solution of 0.2mg/ml respectively.Sample solution 1mL is taken, according to the production method in step 5, measures its absorbance,
Each sample does three parallel laboratory tests, is averaged, and calculates the polyphenol content in sample.
The Determination of Polyphenols of 2 Fructus Terminaliae Billericae extract of table
As can be seen from Table 2, after two kinds of different process of enriching, Determination of Polyphenols has very Fructus Terminaliae Billericae extract
Big raising, in two of them resin elution processes, the Determination of Polyphenols highest at water elution position.
9 Fructus Terminaliae Billericae extract of embodiment is in vitro to the influence of xanthine oxidase
The present embodiment verifies Fructus Terminaliae Billericae extract (TB-1, TB-2, TB-3, TB-1W, TB-15, TB-19, TB-2W, TB-
23, TB-27) in vitro to the influence of xanthine oxidase.
(1) experimental procedure
1, the preparation of phosphate buffer solution: the K of 19.48g is weighed2HPO4·3H2The KH of O and 1.99g2PO4It is dissolved in 500mL
In distilled water, it is made into the phosphate buffer solution (pH=7.5) that concentration is 0.2mmol/L；
2, the preparation of xanthine substrate solution: weighing xanthine 15.2mg, is dissolved in 250mL distilled water, is made into concentration
For the xanthine substrate solution of 0.4mmol/L；
3, the preparation of xanthine oxidase solution: taking xanthine oxidase 5U, is diluted to above-mentioned phosphate buffer solution
160mL is made into the xanthine oxidase solution that concentration is 80U/L, 4 DEG C of preservations；
4, the preparation of sample and positive control solution: precision weigh sample sets Fructus Terminaliae Billericae extract (TB-1, TB-2, TB-3,
TB-1W, TB-15, TB-19, TB-2W, TB-23, TB-27), allopurinol (as positive control), respectively with dimethyl sulfoxide it is molten
Solution, distilled water dilution are made into the solution that concentration is 0.05mg/mL and are tested that (wherein the ultimate density of dimethyl sulfoxide is less than
1%).
5, inhibiting effect is tested:
Sample sets test: 200 μ L of xanthine substrate solution, 100 μ L of sample solution and Huang are sequentially added in 2mL centrifuge tube
200 μ L of purine oxidase solution, the concussion that is vortexed is placed in 25 DEG C of water-baths for 5 seconds reacts 5 minutes, is added after completion of the reaction
1.5mL dehydrated alcohol, be vortexed the concussion reaction of termination in 5 seconds.Reaction solution through 3500rpm be centrifuged 5 minutes, draw 200 μ L to 1.5mL from
In heart pipe, the UA value of each sample is detected respectively with Biochemical Analyzer, each sample operation repetitive is averaged three times.
Blank control group test: it is molten that 200 μ L of xanthine substrate solution, phosphate-buffered are sequentially added in 2mL centrifuge tube
200 μ L of 100 μ L of liquid and xanthine oxidase solution, with the UA value of method detection blank control group, operation repetitive is averaged three times.
Positive controls test: 200 μ L of xanthine substrate solution, positive control solution are sequentially added in 2mL centrifuge tube
200 μ L of 100 μ L and xanthine oxidase solution, with the UA value of method detection positive controls, operation repetitive is averaged three times.
(2) test result
According to xanthine oxidase inhibiting rate=[(blank control group UA value-sample sets UA value)/blank control group UA
Value] * 100, inhibiting rate is calculated, the results are shown in Table 3.
The activity of 3 Fructus Terminaliae Billericae extract of table inhibition xanthine oxidase
From table 3 it can be seen that Fructus Terminaliae Billericae extract (TB-1, TB-2, TB-3, TB-1W, TB-15, TB-19, TB-2W, TB-
23, TB-27) there is different degrees of inhibiting effect to xanthine oxidase.Wherein Determination of Polyphenols high (TB-1W, TB-2W)
Fructus Terminaliae Billericae extract inhibiting effect is strong, and the terminaliae billericae,fructus polyphenol demonstrated in Fructus Terminaliae Billericae extract may be inhibition hyperuricemia
Critical active site.
Influence experiment of 10 Fructus Terminaliae Billericae extract of embodiment to hyperuricemia mouse
This experiment is that influence of the Fructus Terminaliae Billericae extract to hyperuricemia mouse is verified by zoopery.
(1) experimental method
Healthy male KM mouse 130, weight 15-18g are taken, is provided by Shanghai Ling Chang Biotechnology Co., Ltd；It presses
After every cage 5 only carries out point cage processing, weight collection is chosen in adaptive feeding 4 days in the barrier system of company from 130 mouse
In 120 mouse be divided into 12 groups by weight stochastic averagina, every group 10, respectively blank control group, hyperuricemia model
Group, positive controls, test sample group, wherein totally 9 groups of test sample group, respectively code T B-1, TB-2, TB-3, TB-1W,
The Fructus Terminaliae Billericae extract of TB-15, TB-19, TB-2W, TB-23, TB-27.
The modeling of hyperuricemia:
Laundering period carries out gastric infusion to mouse immediately later, and every morning stomach-filling 1 time, wherein test sample group, sample
It is suspended with pure water, carries out stomach-filling according to 30mg/kg；Positive controls Febuxostat is suspended with pure water, according to 1mg/
Kg carries out stomach-filling；Blank control group and hyperuricemia model group are compareed with pure water stomach-filling, and continuous gavage 7 days；
Intraperitoneal injection modeling is carried out to mouse after morning stomach-filling 0.5 hour the 7th day, wherein blank control group is injected intraperitoneally
0.5% sodium carboxymethylcellulose (CMC-Na) solution；Hyperuricemia model group, positive controls and test sample group inject oxygen
Piperazine acid potassium (OA) is dissolved with sodium carboxymethylcellulose (CMC-Na) solution, and injection volume is 300mg/kg weight；
Blood was collected for the eyeball of excision mouse after intraperitoneal injection 1.5 hours, and blood sampling capacity is not less than 0.5mL, blood specimen collection
Afterwards in being placed at room temperature for about 1 hour, it is centrifuged 10 minutes under the conditions of 3500rpm/4 DEG C after blood solidifies completely, takes serum same
It is multiple from 5 minutes Deng under the conditions of, then take 0.2mL serum to use Biochemical Analyzer detection uric acid level (UA)；
It is for statistical analysis to data with Excel and SPSS, average and standard deviation (SD) are calculated, through single factor test variance point
The group difference of more each experimental group after analysis, compared with blank control group, hyperuricemia model group, positive controls and tested
The serum uric acid level of sample sets mouse significantly improves, and has significant difference, shows modeling success.
(2) experimental result
Influence of 4 Fructus Terminaliae Billericae extract of table to hyperuricemia model mice serum uric acid content
(###It indicates to compare P < 0.001 with blank control group；*: with model group ratio, P < 0.05；* expression is compared with model group
P<0.01；* * indicates to compare P < 0.001 with model group) (t-test inspection)
As seen from Table 4, for test sample group compared with hyperuricemia model group, each crude extract of terminaliae billericae,fructus has certain drop
Uric acid effect, the three kinds of different solvents extracts used do not have significant difference.It refines in Fructus Terminaliae Billericae extract, two kinds of different trees
The water elution position of rouge all has the effect of the reduction uric acid of highly significant, and effect is due to other different ethanol concentration elution portions
Position.The above results it can be proved that Fructus Terminaliae Billericae extract have the function of reduce uric acid, and terminaliae billericae,fructus total polyphenols enrichment terminaliae billericae,fructus
Extract has the function of significantly more reduction uric acid.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.It is right
For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of variation or
It changes.There is no necessity and possibility to exhaust all the enbodiments.And it is extended from this it is obvious variation or
It changes still within the protection scope of the invention.
Claims (2)
1. application of the Fructus Terminaliae Billericae extract as active constituent in preparation treatment antihyperuricemic disease drug, which is characterized in that institute
It states Fructus Terminaliae Billericae extract to be prepared by the following method: taking 2kg terminaliae billericae,fructus, after crushing, with 70% (v/v) the ethyl alcohol room of 16L
After temperature is impregnated 7 days, extracting solution is filtered out, 70% (v/v) ethyl alcohol of 12L is added into filter residue, is impregnated 5 days, filtering merges twice
Extracting solution obtains terminaliae billericae,fructus extracting solution, is concentrated in vacuo to dry, obtains 679g terminaliae billericae,fructus crude extract, yield 33.9%；Take hair
Myrobalan's crude extract 200g is purification raw material, is chromatographed with D101 type macroporous absorbent resin；Purify the quality of raw material and resin
Than for 1:20；Water, 50% (v/v) ethyl alcohol are successively used, 95% (v/v) ethyl alcohol carries out gradient elution, the column of 5 times of each gradient elution
Volume, flow velocity are 2 times of column volume/hours；After elution, by water elution, 50% (v/v) ethanol eluate, 95% (v/v)
Ethanol eluate is concentrated to dryness to arrive the Fructus Terminaliae Billericae extract of purification.
2. application of the Fructus Terminaliae Billericae extract as active constituent in preparation treatment antihyperuricemic disease drug, which is characterized in that institute
It states Fructus Terminaliae Billericae extract to be prepared by the following method: taking 2000g terminaliae billericae,fructus, after crushing, extracted at 80 DEG C with the water of 16L
50min filters out extracting solution, and the water of 12L is added into filter residue, and 30min is extracted at 80 DEG C, and filtering merges extracting solution twice,
Terminaliae billericae,fructus extracting solution is obtained, is concentrated in vacuo to dry, obtains 830g terminaliae billericae,fructus crude extract, yield 41.5%；Take terminaliae billericae,fructus thick
Extract 200g is purification raw material, is chromatographed with Diaion-HP20 type macroporous absorbent resin；Purify the quality of raw material and resin
Than for 1:20；Water, 25% (v/v) ethyl alcohol are successively used, 65% (v/v) ethyl alcohol carries out gradient elution, the column of 5 times of each gradient elution
Volume, flow velocity are 2 times of column volume/hours；After elution, by water elution, 25% (v/v) ethanol eluate, 65% (v/v)
Ethanol eluate is concentrated to dryness to arrive the Fructus Terminaliae Billericae extract of purification.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510341609.XA CN104983758B (en) | 2015-06-18 | 2015-06-18 | A kind of medicinal usage of Fructus Terminaliae Billericae extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510341609.XA CN104983758B (en) | 2015-06-18 | 2015-06-18 | A kind of medicinal usage of Fructus Terminaliae Billericae extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104983758A CN104983758A (en) | 2015-10-21 |
| CN104983758B true CN104983758B (en) | 2019-04-26 |
Family
ID=54295747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510341609.XA Active CN104983758B (en) | 2015-06-18 | 2015-06-18 | A kind of medicinal usage of Fructus Terminaliae Billericae extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104983758B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106491669A (en) * | 2016-10-20 | 2017-03-15 | 新疆医科大学 | A kind of extraction process of Fructus Terminaliae Billericae sarcocarp polyphenol |
| CN108159216A (en) * | 2018-02-22 | 2018-06-15 | 季飞 | Treat the Chinese medicine composition of gout |
| CN109453212B (en) * | 2019-01-06 | 2021-12-14 | 北京中医药大学 | A fructus Terminaliae Billericae extract with anticancer effect and its effective components preparation method |
| CN111973638A (en) * | 2020-09-02 | 2020-11-24 | 济宁医学院 | Application of fructus terminaliae billericae extract and fructus terminaliae billericae polyphenol |
| CN112168852A (en) * | 2020-11-25 | 2021-01-05 | 内蒙古自治区农牧业科学院 | Ultrasonic extraction process of myrobalan total flavonoids |
| CN112603940A (en) * | 2021-02-03 | 2021-04-06 | 江西中医药大学 | Preparation and application of active extract of gout decoction powder for resisting hyperuricemia and gout diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940216A (en) * | 2015-06-10 | 2015-09-30 | 苏州禾研生物技术有限公司 | Application of galloyl-glucoside derivative and pharmaceutical composition for treating hyperuricemia |
-
2015
- 2015-06-18 CN CN201510341609.XA patent/CN104983758B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940216A (en) * | 2015-06-10 | 2015-09-30 | 苏州禾研生物技术有限公司 | Application of galloyl-glucoside derivative and pharmaceutical composition for treating hyperuricemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104983758A (en) | 2015-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104983758B (en) | A kind of medicinal usage of Fructus Terminaliae Billericae extract | |
| CN104383292B (en) | Application of the dendrobium candidum extract in prevention and/or treatment antihyperuricemic disease drug is prepared | |
| CN105520984A (en) | Novel medicinal application of coreopsis tinctoria | |
| CN102755386B (en) | Antivirulent drug composition, and preparation and application thereof | |
| CN104546995B (en) | A kind of medicinal usage of emblic extract | |
| CN102327368A (en) | Chinese lizardtail rhizome or herb rootstock total effective fraction and preparation method and application thereof | |
| CN103860638B (en) | Preparation method of sophora alopecuroide flavonoid composition and new medical application | |
| CN109893538A (en) | New application of the carbene class in anti-trioxypurine | |
| WO2018133563A1 (en) | Panax plant extract and pharmaceutical composition and use thereof | |
| CN1484529A (en) | Gusuibu extracts for trvating osteoporosis and method for extracting same | |
| CN104224863B (en) | Lysimachia herb total flavone is preparing the application in treating antihyperuricemic disease drug | |
| CN105287709B (en) | A kind of Hickory Leaves extractive total flavone as well as preparation method and application thereof with anti-trioxypurine effect | |
| CN100478001C (en) | Tribulus terrestris extraction and its preparation method and use | |
| CN101912594A (en) | Traditional Chinese medicine preparation for treating gastrointestinal diseases | |
| CN108057064B (en) | Corydalis tuber total alkaloid gastric floating tablet | |
| CN101677989A (en) | A drug composition for treatment and prevention of ischemic stroke and its preparation methods | |
| CN114794478B (en) | Composition capable of reducing blood pressure, blood lipid and blood sugar and application | |
| CN100444849C (en) | New use of tribulus terrestris extraction | |
| CN103301134B (en) | Pharmaceutical composition for treating hyperlipidemia as well as preparation method and applications | |
| CN101766664A (en) | Extraction method of total saponin of Radix Ilicis Asprellae and quality detection method thereof | |
| CN110960569A (en) | Phyllanthus emblica extract and preparation method and application thereof | |
| CN101693059B (en) | Preparation method of rose polyphenol and application thereof in gynaecology and obstetrics | |
| CN100584358C (en) | Traditional Chinese medicine composition for treating cardio cerebrovasculer disease and its preparations and preparation method | |
| CN105012294B (en) | New application of the ellagic acid compounds in treatment antihyperuricemic disease drug is prepared | |
| CN102018740B (en) | Medicinal composition containing extracts of leaves of helianthus and application of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |